OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
November 4, 2025
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, operator, and good afternoon to you all. Speaking is Kurt Gustafson, and I serve as Chief Financial Officer at OmniAb. We appreciate everyone for tuning in to this conference call covering our financial results for the third quarter of 2025. Slides have been prepared to go along with the remarks we'll make today, and you can find them on our website, omniab.com, under the Investors section. Prior to getting started, a reminder is in order for our audience: anything said on this call by OmniAb's management will contain forward-looking statements as defined under the federal securities laws. Risks and uncertainties are part of these forward-looking statements, and those could lead to actual results differing materially from any results that are anticipated. The cautionary statements included in today's press release, along with our SEC filings, qualify these forward-looking statements. One important point: the information discussed on this conference call is time-sensitive, and it holds accuracy only as of the moment of the live broadcast, which is today, November 4, 2025. OmniAb assumes no duty to revise or update any forward-looking statements so they reflect events or circumstances arising after this call's date, except where the law demands it. With me this afternoon is Matt Foehr, who serves as OmniAb's President and CEO. On today's call, we'll cover highlights regarding the company's business and operations, updates on our partners and technology, and also our recent financial results and outlook. Once the prepared remarks are finished, we'll take questions. So with that said, I'll hand things over to Matt.
Matt Foehr
executiveThank you, Kurt. Hello, everyone, and I appreciate you being with us on our Q3 call. Let's begin on Slide #4. We keep seeing solid deal activity all through the third quarter, and the count of new programs brought on this year is well ahead of the prior year's pace. By the close of Q3, our program additions had already matched the total additions for the entirety of 2024; on top of that, we've expanded and broadened our roster of active partners, hitting an all-time peak, which now stands above 100. To us, this confirms the strength of our distinctive proprietary technology platforms and the demonstrated worth they deliver in helping our partners uncover next-generation therapeutics; we are establishing the essential momentum behind our newly introduced xPloration partner access program, which was built to place our high-throughput single B-cell screening platform directly with our partners. Our xPloration sales funnel keeps expanding, creating significant interest and fresh opportunities on our end; and as the most recent proof of our dedication to breakthrough innovations and leadership in the sector, this December, we will introduce an entirely new technology into our stack. We're delighted to offer a brief preview right now of OmniUltra, the very first transgenic chicken capable of producing cow-like antibodies featuring ultra-long CDRH3s. OmniUltra could unlock new markets and fresh business prospects for us, while extending our ability to help enable the discovery of novel peptide therapeutics. I'll say more about this technology shortly. Even as we keep increasing our partner and program counts, we also restructured staffing levels during Q3 and cut operating expenses further to generate efficiencies within our lean but scalable operating model; what's more, we boosted our financial flexibility and reinforced our balance sheet by completing a $30 million private placement in late August. I'd like to extend a welcome to our new shareholders and express gratitude to the existing shareholders who took part in the transaction for their backing. Now turning to a look at our key business metrics, beginning on Slide #5. We closed Q3 with 104 active partners. In the third quarter, we noted that we finalized new license agreements with A*Star and the University of Leeds. The breakdown of our active partners by category — discovery, commercial and academic — remains stable; the same is true of how our partners are distributed geographically, with slightly more than half located here in the U.S; and I'd point out that our international footprint has kept expanding as we make a focused push to grow and diversify our partnership base. When it comes to new partnerships, we increasingly believe there are creative approaches to generating value across differing time horizons, by making use of our technologies or the assets produced by our novel technology development and validation efforts. On Slide 6, the total of Active Programs using our technologies rose to 399 by the end of Q3. Year to date, we've added 36 programs on a net basis, and 18 of those came in during Q3, as momentum for adding programs stayed strong. In Q3, 6 programs were ended. Program attrition, as I've mentioned many times, is simply a routine aspect of what we do, and it will keep happening because partner priorities shift, and because of budget and technical considerations at our partners. The graphics on Slide #7 show how our post-discovery stage programs in the portfolio have grown, along with how those programs have advanced into and through clinical development. Post-discovery stage program count rose 15% compared with a year earlier. Several new programs advanced into the preclinical stage. And during Q3, 1 program reached the registration phase; these 61 post-discovery stage programs carry contracted remaining potential milestones to OmniAb of roughly $1.3 billion, with $700 million of that coming from small molecule ion channel programs. Slide 8 presents the count of active clinical programs and approved products, which came to 32 at the close of Q3. As of September 30, 2 new partner programs had entered the clinic this year, while 2 exited. We're pleased to share that after the quarter ended, the first program derived from OmnidAb entered human clinical trials. Since we introduced the OmnidAb single-domain discovery platform under 2 years ago, this marks an important milestone for a new technology, particularly in such a brief span. We also got confirmation that one more bispecific antibody stemming from our rodent platforms entered human clinical trials just last week; we'll share more about both of those new clinical programs once our partners have made additional details public. All told, based on our recent conversations with partners and our visibility into their efforts, we anticipate as many as 5 new entries into clinical development for novel OmniAb-derived programs during this year. That sits at the low end of the range we previously projected for clinical starts, mainly because certain partners have simply pushed the timing of clinical program initiations to early 2026. On the subject of clinical programs, I'd also note that multiple partners will present data at the ASH Annual Meeting in early December. So that's something else we're looking forward to. Now to Slide 9. Here we've called out select recent updates on partner programs that use our technologies. At the Annual Meeting of the American Thyroid Association, Immunovant presented 6-month durability data from its Graves' disease study, showing sustained remissions with batoclimab. Its next-generation candidate, IMVT-1402, is moving ahead in 2 potentially registrational Phase III trials in Graves' disease, with top line results anticipated in 2027. Over to the right on this slide, at ESMO, Arcus Biosciences reported median overall survival of 26.7 months from its Phase 2 EDGE gastric trial. This research pairs domvanalimab alongside zimberelimab, which comes from OmniAb, plus chemotherapy, for treating advanced gastric cancer — a clear boost to the promise of this therapeutic strategy. China's NMPA has accepted the NDA for SAL003, Salubris Bio reported; SAL003 is a recombinant fully human anti-PCSK9 antibody aimed at dyslipidemia. As a result, during Q3 this program advanced out of our Phase III bucket into the registration stage. Then, an abstract from Rondo Therapeutics covering its first-in-class CD28 and Nectin-4 bispecific antibody got accepted for a presentation at the Society for Immunotherapy of Cancer Meeting, happening this week. Now let's move to Slide 10. On it, we call attention to our pipeline of clinical and commercial stage partners for Active Programs that bring downstream economics to OmniAb. Where a program sits in this graphic reflects its most advanced status across any geography or indication. Our partners keep pushing OmniAb-derived antibodies into the clinic and beyond; and this newest update reflects Salubris Bio's SAL003 advancing into the registration phase, as I noted earlier. Moving to Slide #11, I want to spend just a brief moment calling attention to the progress of our xPloration partner access program. What we're hearing early from partners who use the instrument is that xPloration delivers exceptionally well and generates efficiencies within discovery workflows. The response so far has us quite pleased, since xPloration keeps building momentum following its Q2 launch, with robust demand for lab demos from partners across Q3.
Matt Foehr
executivexPloration's usability and effectiveness set it apart in a meaningful way. This offering works hand in hand with our primary business of licensing technology, since we anticipate that xPloration will boost earnings and cash flow over both near-term and longer horizons. As our installed fleet of instruments expands, we look for our revenue streams to widen through repeat sales of single-use consumables, plus yearly subscription offerings covering software and maintenance agreements. In the end, it's evident to us that xPloration strengthens ties with partners, could fuel growth in new programs, and highlights OmniAb's creativity in bringing together automation, AI-driven approaches, and discovery. Now on Slide #12. Our in-house innovation efforts keep sharpening our competitive edge, particularly through an expanding portfolio of discovery platforms built on genetically modified chickens. We have a long track record of leading the way in creating sophisticated discovery technologies that the field requires. We frequently discuss the benefits a chicken immunization host offers for finding novel molecules, given that roughly 50% of therapeutic targets show more than 90% conservation in mammals. Thus, employing a chicken as the immunization host species during discovery may prove truly crucial and truly beneficial in numerous cases. Our OmniChicken technology, pictured at the bottom left of this slide, is still the sole validated humanized transgenic chicken globally for antibody discovery. By exploiting the evolutionary gap separating birds from mammals, OmniChicken produces strong immune reactions and yields remarkably varied antibody repertoires. This platform has turned into a cornerstone for numerous discovery pipelines among our partners. On top of that, OmniClic brought in a fixed light chain design, allowing effortless pairing of antibodies for bispecific and multi-specific uses. Meanwhile, OmnidAb, our single-domain antibody framework, stretches the applicability of chicken-derived antibodies into compact, stable therapeutic formats and creates possibilities spanning various modalities. Molecules derived from OmnidAb fit well with modular and multi-specific architectures while preserving benefits regarding manufacturability and stability; and as I noted, OmnidAb came to market under 2 years back, and it has drawn many new partners and already produced a program that has reached the clinic. And now, as the newest addition to this lineup, in December, we are introducing our latest transgenic chicken platform, branded OmniUltra. On to Slide #13. OmniUltra marks the next step forward in discovery tools, being the first and only transgenic chicken that produces ultra-long CDRH3s, a structural antibody trait normally observed just in cows. To phrase it differently, OmniUltra chickens are built to generate antibodies possessing the physical traits present in cows, yet carrying human characteristics that render them appropriate for human therapeutics. These ultra-long CDRH3s are intended to let antibodies access distinctive heat or recess binding pockets and epitopes that were previously unreachable, possibly revealing therapeutic possibilities past what standard antibodies or standard modalities can achieve. What's particularly thrilling is the possible capacity of these ultra-long CDRh3s to be extracted as novel or standalone binding fragments called Pico bodies, which rank as the smallest functional antibody fragment known, about 1/3 the size of an antibody. Pico bodies might unlock completely novel therapeutic uses and approaches. If we move to Slide 14 now; OmniUltra, then, isn't just pushing past the limits of what antibody discovery technologies can do — it may also create brand-new possibilities for us in therapeutics built on peptides. In addition to that novel architecture, OmniUltra was designed for in vivo optimization, which permits molecules to basically be preselected for specificity, affinity and structural stability. Through this process, antibodies featuring unique binding domains are discovered more readily, with the potential to hit epitopes that were previously inaccessible. Also, and this is a key point, peptide therapeutic discovery is another area where OmniUltra can be put to work. Peptides are a type of molecule that the industry has been paying a lot more attention to, mostly due to the GLP-1 medications that have been so important for patients and for the sector globally. That attention has fueled major expansion and spending in peptide therapeutics when it comes to discovery, development, and the capacity and infrastructure further downstream. That's part of why we think OmniUltra has arrived at a really favorable moment. Unlike the usual ways peptides are discovered, OmniUltra uses a transgenic chicken as its host, producing optimized structured peptides biologically on a validated scaffold. This kind of capability might open up new categories of therapeutics made through biological means, with possible uses spanning different modalities. OmniUltra demonstrates how our team leads on innovation, and it carries our platform's edge into additional therapeutic areas — which sets our technology further apart and strengthens the growth opportunity we see over the long term. A formal launch of OmniUltra is laid out on Slide 15, with the plan being to hold it at the Antibody Engineering & Therapeutics Conference in San Diego next month. We have 2 podium presentations and 2 poster presentations at AET. Today's short preview doesn't capture everything there is to say about OmniUltra. So during AET, an investor webcast tied to the OmniUltra technology will be held, where we'll talk through potential market use and applications and go over how this highly innovative and pioneering technology could affect the business. Our validation efforts with OmniUltra spanned a wide range of therapeutic targets, and we'll cover that effort too. As the event draws nearer, we'll share the webcast specifics. For the moment, though, please note Monday, December 15, at 5:00 p.m. Eastern Time on your calendars. Now let's turn to Slide 16. OmniUltra's prospects have us enthusiastic, since it greatly expands the pool of possible partners we can pursue in peptide discovery, while clearly creating fresh avenues and chances in antibody discovery too. For those of you who keep up with our company, you're probably aware that our tech licensing agreements typically consist of multiple pieces — things like revenue from collaboration and services, payments tied to milestones, and royalties once a program reaches commercialization. One thing I'd like to emphasize is that OmniUltra is built on top of the transgenic chicken platform we've already established, and that platform depends on a service agreement because our partners aren't able to carry out the discovery work themselves. We believe this new OmniUltra offering has the potential to boost collaboration and service revenue in the near term. With that said, I'm going to hand it over to Kurt, who will take us through the Q3 figures. Kurt?
Kurt Gustafson
executiveThanks, Matt. Moving to Slide 18, I'll begin by walking through revenue. For Q3 of 2025, our reported revenue came in at $2.2 million, compared with $4.2 million during the same quarter in 2024. That decline was mainly driven by fewer milestones being achieved along with reduced service revenue. The drop in service revenue largely stemmed from wrapping up a couple of small molecule ion channel programs earlier in the year. Partially offsetting that decrease, the third quarter of 2025 brought in xPloration revenue from consumables sales, plus a slight bump in royalty revenue. Now on Slide 19, we lay out cost and operating expense for Q3 2025, which fell to $20.4 million from $23.9 million in the prior year period; both R&D and G&A expenses came down versus last year, and this quarter also carried a nonrecurring charge of roughly $800,000 tied to a headcount reduction we carried out earlier in the quarter. Moving to Slide 20, I'll highlight a few operating expense line items, beginning with R&D expense, which dropped to $10.4 million from $13.3 million in the year ago period, mostly because of lower headcount and stock-based compensation, along with reduced external expenses following the completion of certain ion channel programs earlier this year. G&A expense came to $6.8 million in Q3 2025 versus $7.1 million for the same period in 2024, with that decrease mainly attributable to lower legal fees and stock-based compensation expense. Net loss for the third quarter of 2025 totaled $16.5 million, or $0.14 per share, compared with a net loss of $16.4 million, or $0.16 per share, for the same period in 2024. On Slide 21, we show our balance sheet as of September 30, 2025. We closed the quarter with $59.5 million in cash; and as Matt noted, during the quarter we completed a $30 million private placement of common stock, which brought in $28 million net to the company. I'll wrap up on Slide 22 by discussing our 2025 financial guidance. We recently learned that a few milestones we had expected in the second half of 2025 will now shift into 2026. We also found additional efficiencies within our operating structure. Consequently, we're revising our guidance for this year; we now anticipate 2025 revenue between $18 million and $22 million, with operating expense between $82 million and $86 million. As a reminder, roughly 40% of our operating expense is noncash, mostly from stock-based compensation and the amortization of intangibles, primarily tied to historical company or technology acquisitions. We still expect cash used in 2025 to be lower than cash used in 2024, excluding financings in both years. We anticipate that the cash balance at year-end will fall somewhere in the range of $52 million to $56 million; and lastly, when it comes to the tax rate, our guidance stays the same, at around 0%, which is because of a valuation allowance. So with that said, I'd like to begin the Q&A portion of the call. Operator?
Michael Almisry
analystMicheal Sonntag is filling in for Puneet. Nice work on the quarter. For my first question, I'd like to focus on the private placement. I'm wondering whether you could give us some detail regarding what drove the decision on when to do the placement, and do you have any view on the cash runway that this provides now — do you anticipate that it carries you to the point where you're consistently at cash flow breakeven?
Kurt Gustafson
executiveYes. Perhaps I'll give a bit more, or share a few thoughts, and then maybe Matt can chime in; these are discussions we hold with our Board; we reviewed our forecast and concluded the timing was right to, in a sense, bolster the balance sheet. Markets appear to be turning somewhat more favorable. And so we seized that chance to strengthen the balance sheet. We don't give any kind of long-term guidance. I sort of provided the guidance we have for this year when it comes to cash burn and cash balance. But I believe this leaves us in a good spot. I feel the company is now well capitalized. I don't know, Matt, anything else to add?
Matt Foehr
executiveRight, and let me jump in too. Once again, this gives the business a degree of flexibility, and it was a sensible move; like Kurt mentioned, we believe the company is in a strong capital position. Looking ahead to the years to come, we'll share more guidance, though we're feeling positive about our current standing.
Michael Almisry
analystAll right, that's excellent. Then, regarding xPloration, could you share a bit more detail about the discussions you're having with customers? Which types of customers within your partner base are showing greater interest? Also, any perspective on bookings or the timing of orders would be useful — whatever insight you can offer.
Matt Foehr
executiveSure, Michael. Things have been extremely active when it comes to xPloration, and the level of interest has been really robust. Broadly speaking, our partner universe now stands at 104 partners. The partners who are most engaged — and probably the ones positioned to gain the most from xPloration — are clearly those in the higher tier. We've had a very full schedule running demos at our Emeryville site, and at certain partner locations too. That, I think, is a promising sign for how everything is coming together. Of course, purchasing the instrument itself through xPloration represents a capital expenditure, and our launch timing feels like it was well chosen — being heavily occupied with demos during Q3 and on into Q4 lines up nicely as partners work out their budgets for 2026 and their plans for capital spending. So we're pleased with our position. What we've heard back has been quite favorable concerning how efficient the instrument is, how easy it is to operate, and the wide range of lab users who can take advantage of xPloration. So that leaves us feeling confident.
Analyst
analystAm I coming through? Sara here, filling in for Joe. Apologies if I was on mute.
Matt Foehr
executiveSara, we've got you now.
Analyst
analystYeah. I just had a question about OmniUltra. I was hoping to understand how ready it is for launch, and whether you could, right now, go into more detail on that readiness? Have any beta or pilot projects wrapped up yet, or are there potential partners already committed to adopting the platform when it goes live next month?
Matt Foehr
executiveYes. Yes, Sara. We've carried out a considerable amount of validation work on OmniUltra involving a great many targets that we understand the industry cares about. That's effort we've been conducting in-house. And it's partly why we're bringing the technology to market with 2 podium presentations at the AET conference. So at the scientific conference, when launch happens, we'll discuss that particular work in far greater detail. So we have a very solid understanding of how broadly this technology can be applied, and I believe we're very well positioned for the December launch; so hopefully, that addresses your question.
Alex Xenakis
analystAlex here, filling in for Kripa. We've got another question about xPloration. The conversations seem to be going quite well. Is there any update on the new thinking regarding how much revenue xPloration can bring in, and over what timeframe?
Matt Foehr
executiveYes, obviously it's still early days for the xPloration launch. We've stated that we expect xPloration to be accretive to both earnings and cash flow in the short term and the long term. A lot of that relates to how the technology was designed and how we're rolling out the launch. Multiple revenue streams are tied to xPloration. There's the instrument sale itself, of course, which generates revenue, and we have a solid margin on that instrument. Beyond that, we have single-use proprietary consumables, plus service contracts and maintenance contracts. So no precise guidance has been provided by us at this point. I think as we move through the launch and as more instruments get sold and deployed, we'll gain more visibility there, but we feel really good about its positioning.
Alex Xenakis
analystGot it, that's clear. Now for a small additional question. Do you also show the tech and your collaborations at other industry expos? Or does that mostly happen via one-on-one talks straight with the firm?
Matt Foehr
executiveNo, we also attend expos where we're aware our partners are going to be. In fact, besides introducing OmniUltra at AET, for example, we'll likewise have a big xPloration footprint there too. And we've got several others scheduled too, where we'll bring demo units and run either virtual or arrange face-to-face demos alongside partners.
Matt Hewitt
analystMaybe to kick things off, it sounds like you had — and I get that this is simply the nature of the business — but a few customers of yours delayed programs into 2026; milestones you'd expected later in the current year slipped to '26. Are you noticing any uptick? This earnings season, we've been hearing from a number of companies that with M&A being quite active and the funding climate improving for small and midsized pharma, R&D budgets are sort of returning, that spending is picking up. And I'm just wondering whether this is merely an isolated situation involving a handful of partners? Or are you observing somewhat more of a widespread pattern of things sliding to 2026?
Matt Foehr
executiveYes. Thanks, Matt. I mean, on a broad level, and we really flagged this beginning late in Q4 of last year, with solid momentum in program additions, correct? We're witnessing ongoing momentum in program additions that has carried through this year, which is great to see; and I believe we're still seeing momentum in that area. The link, or the piece about milestones slipping into 2026, in this case I'd label that as more of what I'd call routine development matters, right? So it's the timing of clinical batches or processes during clinical start-up, that sort of thing. In certain cases, these were programs where partners had told us of their intent to begin in Q4 and had also made that plan public, yet simply due to routine development items had moved into early 2026. So a range of reasons; but we are seeing, similar to what you described regarding industry momentum, we're seeing that through strong program additions. What's interesting is we're also seeing, with certain academic partners, a greater emphasis on creating spin-out companies around assets and being far more focused on monetizing programs and assets that have emerged or could emerge from our technology; so that's sort of another intriguing thing we're beginning to observe too; but hopefully that provides you with some color.
Matt Hewitt
analystNo, that helps a lot. Then perhaps something along a similar vein here, though — and I know it's still early, we're in October. But when you have those discussions with your partners, what are you picking up regarding '26 R&D budgets? I believe there was quite a bit of, I suppose, optimism that the 2025 budgets look fairly strong compared with '24. And I know there have been some fits and starts over the course of the year, but it does seem like perhaps those budgets will end up being spent. Do the conversations suggest, more or less, that an uptick in R&D budgets could be coming? And I suppose, related to that, with xPloration, is your expectation from the feedback you're receiving that this is a Q1 purchase decision? Or might you still see some of these boxes sold before this year is out?
Matt Foehr
executiveYes. Matt, so perhaps our — one of the strongest gauges we have comes in the shape of program starts, correct? That's genuinely what we observe: when a new program begins for a novel target, right, a great deal of work involving novel biology happens upstream of that on the partner's side. They've clearly dedicated a project team, and they're launching a program; so that, once again, we've witnessed really solid, strong momentum in program additions this year, and that has been encouraging to watch. So I'd say that's a solid indicator. The majority of our particular talks concerning budget and budget planning as of late have revolved around xPloration, and that really sits just within the capital space. And then the precise timing of orders further downstream can clearly hinge on a range of factors at the partner, in terms of which work they're performing and when, and how they're phasing their capital spend through 2026. So yes, that's roughly what we're observing.
Brendan Smith
analystPerhaps I could start with a quick question about OmniUltra. I completely recognize that it's still early days, but could you help us grasp how you're all evaluating the possible economics behind a few of those partnerships — perhaps in relation to a few of your other offerings, or ones already on the books? And do you imagine there might be varying terms depending on how they intend to apply it, whether that's for peptides or antibodies, or whatever the case may be? And also, do you think any of those might in certain situations take the place of some partnerships that already exist?
Matt Foehr
executiveYeah, Brendan, we see OmniUltra as expanding the business rather than replacing anything. It applies across a wide range of uses and opens up fresh territory for us. Obviously, we've got a big, steady network of antibody-focused collaborators, and that number stands at 104 right now. Many of them have expressed — or will express, or already did express — curiosity about OmniUltra for applications like CAR-T treatments or bispecifics. We also work with quite a few partners in radiopharma, another area that's expanding quickly, and I expect that will keep growing. On top of that, this brings in a completely different group of possible collaborators who care about peptide discovery. A number of our bigger partners are doing work with peptides in addition to antibodies. At the same time, we're seeing an entirely different group of partners whose primary focus is peptides. That shift has grown substantially across the past two years, driven by wins in areas like GLP-1 drugs and similar products. As a result, significant money is being put into the peptide area. We view this as complementary. Regarding how agreements get structured, my sense is that near-term chances to generate service revenue will emerge for us, and there are several reasons why. You can also find plenty of examples of deals in peptide discovery that fit the structures we've established, which include payments made upfront, fees for services, milestone-based payments, and royalties. That said, the exact conditions will clearly depend on how a range of elements tied to each particular license interact.
Brendan Smith
analystAll right, understood. And perhaps very briefly, if I may, one more question. Regarding the partner pipeline — could you share a bit about how you're viewing the early trajectory for a few of those royalty streams? I realize it's somewhat a spread of distinct areas where you have partnerships, spanning FcRns, PCSK9, and PD-1. So I'm simply curious where you might anticipate the quickest chance for certain royalties to expand, as opposed to others that could need more time before they're fully up and running?
Matt Foehr
executiveYeah. Yeah. Perhaps I'll speak at a high level about a few of the programs, and after that Kurt might address a bit about the revenue in general, specifically the modeling side of how milestones and royalties factor in. But clearly right now, there are 2 drugs sitting in the registration bucket, and both are presently in China. The most recent is SAL003, the anti-PCSK9 you brought up; so that was news from just 4 weeks, 5 weeks ago out of Salubris. And they said they had filed their NDA submission; it got accepted in China. In their public disclosures they noted that the NDA is consistent with China's accelerated approval framework for high-impact biologics. So that was broadly encouraging to hear. And they've said publicly they're aiming for market entry in 2026; they've also emphasized comparable or superior efficacy relative to other anti-PCSK9 therapies and one that was — that was developed domestically within China. So we'll keep watching that closely. That drug originally emerged from our early partnership with WuXi for our rodent platforms, and it carries a 3% global royalty. So that's likely the more recent one; and then when you look at the Phase III assets and Phase II assets, quite a few there are getting appropriate attention from folks. Immunovant is doing excellent work on IMVT-1402 and has a few anticipated data events next year that we're clearly monitoring. Acatilimab with Genmab is likewise in Phase III trials. That's another one drawing attention. And now we're beginning to see mounting interest in Teva's 53408, an IL-15 for celiac, and they're also going after some additional indications. They've been pushing that forward quite aggressively and spotlighting the program; so we're rooting for that too. But Kurt, perhaps you'd like to walk through the...
Kurt Gustafson
executiveYeah. I mean, when it comes to our approach on the royalty ramp, what we usually do is look at what the analyst consensus is for these drugs. So for both acasunlimab and the 1402 compound — I mean, Genmab has publicly stated they expect a 2028 launch. When I look at analyst estimates, that's roughly what they're projecting too, and there's a ramp that goes along with it. It's the same with — similar timing for 1402; so we look at those analyst expectations when it comes to how we model the royalties we might eventually receive. And they're pretty nice ramps, and people have pretty nice forecasts tied to both of those compounds. They're expected to be very large drugs.
Analyst
analystThis is Josh, filling in for Steve. I had one brief question regarding OmniUltra and what sets it apart from OmniTaur. If I recall correctly, the OmniTaur platform seemed quite comparable when it came to this generation of those ultra-long CDR3s or CDRH3s. Might you offer a bit of insight into what actually makes these platforms different?
Matt Foehr
executiveYes. Excellent question, Josh; and I'll do my best not to get overly geeky or technical. OmniTaur, in fact, makes use of cows, correct? So the sequences come from cows; and beyond that, we've built certain downstream workflows and other elements that create value within OmniTaur; and we currently have quite a few active OmniTaur programs, a portion of which have reached the preclinical stage and are nearing IND. OmniUltra makes use of a chicken host to capture that benefit of evolutionary distance, correct? That means you can take advantage of how far chickens are from mammals in order to provoke a more potent immune response. And we've additionally engineered in certain other attributes that have expanded, in a sense, how broadly OmniUltra can be applied across a range of areas, including unlocking possibilities within the peptide space. So fundamentally, the host is what differs, though clearly there are quite a few additional finer technical specifics that extend how broadly OmniUltra can be applied.
Analyst
analystAll right, that's helpful. Now I have one more thing about xPloration revenues. Could you possibly give us some detail on how that splits among consumables, software, and hardware? Also, do you expect that at some point you might share some sort of metrics covering the sales mix for the xPloration platform?
Matt Foehr
executiveYeah. No, that's a fair question. My sense is we won't really have a breakdown ready for you during this quarter. Revenue from it wasn't very large. What I'd say is that it's largely tied to consumables. With the xPloration launch, I'd say we're still in the early stages. As things develop further, I suspect we'll likely be in a position to give a bit more detail regarding things like average consumable usage per instrument, along with some other metrics of that kind. That said, right now it remains quite early, so keep watching for updates. If the launch keeps moving forward and making progress, we're hopeful we can offer that kind of detail.
Matt Foehr
executiveAlright, thanks very much, operator. I want to express appreciation to all of you for being with us on this call today, and for the questions and the engagement; we're eager to talk through our Q4 financial results at the start of next year. Until then, we'll be taking part in several investor conferences during the remainder of this month — among them Truist's BioPharma Symposium, happening this week in New York, Stifel's Healthcare Conference, which takes place next week, and the Jefferies Global Health Conference in London. As I noted, on December 15, we will also be — we're going to officially introduce OmniUltra, and an investor webcast is scheduled for that same day. We're looking forward to sharing more specifics about that webcast in the coming month. So thank you once more, and enjoy the rest of your day.
Operator
operatorAppreciate it. Everyone, this call has reached its conclusion. Thanks to each of you for participating. At this point, feel free to hang up your connections.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.